CA2203480C - Interferon conjugates - Google Patents

Interferon conjugates Download PDF

Info

Publication number
CA2203480C
CA2203480C CA002203480A CA2203480A CA2203480C CA 2203480 C CA2203480 C CA 2203480C CA 002203480 A CA002203480 A CA 002203480A CA 2203480 A CA2203480 A CA 2203480A CA 2203480 C CA2203480 C CA 2203480C
Authority
CA
Canada
Prior art keywords
conjugate
ifn
alpha
peg
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002203480A
Other languages
French (fr)
Other versions
CA2203480A1 (en
Inventor
Pascal Sebastian Bailon
Alicia Vallejo Palleroni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21790006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2203480(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CA2203480A1 publication Critical patent/CA2203480A1/en
Application granted granted Critical
Publication of CA2203480C publication Critical patent/CA2203480C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Physiologically active PEG-IFN.alpha. conjugates having a formula as follows: (see formula I)

Description

Interferon, in particular interferona2a, is a pharmaceutically active protein which has antiviral and antiproliferative activity. For example interferon is used to treat hairy cell leukemia and Kaposi's sarcoma, and is active against hepatitis. In order to improve stability and solubility, and reduce immunogenicity, pharmaceutically active proteins such as interferon may be conjugated to the polymer polyethylene glycol (PEG).

The bioavailability of protein therapeutics are often limited due to their short plasma half-life, thus preventing them from attaining their maximum clinical potency. In recent years, PEG conjugated biomolecules have been shown to possess clinically useful properties (Inada et al., J. Bioact. and Compatible Polymers 5, 343 (1990);
Delgado et al., Critical Reviews in Therapeutic Drug Carrier Systems 9, 249 (1992); Katre, Advanced Drug Delivery Systems 10, 91 (1993)).
Among these are better physical and thermal stability, protection against susceptibility to enzymatic degradation, increased solubility, longer in vivo circulating half-life, decreased clearance and enhancing potency. It has been reported that branched PEG conjugates exhibit increased pH and thermal stability and greater stability towards proteolytic digestion than linear PEG conjugates. (Monfardini et al., Bioconjugate Chem. 6, 62 (1995)). Other properties of PEG proteins are reduced immunogenicity and antigenicity, as well as reduced toxicity. Another effect of PEGylation of certain proteins may be reduced in vitro activity accompanied by enhanced in vivo activity.
This has been observed in G-CSF (Satake-Ishikawa et al., Cell Structure and Function 17, 157-160 (1992)), IL-2 (Katre et al., Proc.
Natl. Acad. Sci. USA 84, 1487 (1987)), TNF-a (Tsutsumi et al., Jpn. J.
Cancer Res. 85, 9 (1994)), IL-6 (Inoue et al., J. Lab. Clin. Med. 124, 529 (1994)) and CD4-IgG (Chamow et al., Bioconj. Chem. 5, 133 (1994)), among others.

Ar/So 7.3.97 It has been now observed that in the case of interferon, PEGylation reduces in vitro antiviral activity but increases antiproliferative activity in human tumor cells. However the new PEG
interferon conjugate of this invention has surprising properties in that the antiproliferative activity of the PEG interferon is much higher than that not only of interferon but of other PEG interferon conjugates. Although the antiproliferative activity of the conjugate is much increased over other PEG interferon-a conjugates, yet the reduction in antiviral activity is similar. In addition, the PEG
interferon-a conjugate of this invention is non-immunogenic, it elicits virtually no antibody formation. In contrast, other PEG interferon-a conjugates do elicit limited antibody formation.

Accordingly, the invention is a new class of PEG derivatives of interferona (IFN(x). The conjugate of this invention has a branched PEG structure, as can be seen below. The branched PEG has the advantage of allowing the attachment of 2 linear PEG molecules at a single site, thus doubling the attached PEG mass without multiple sites of PEGylation.
Compared to unmodified IFNa (i.e. IFNa without a PEG attached), the conjugate has an increased circulating half-life and plasma residence time, reduced immunogenicity, decreased clearance, and increased antiproliferative activity, concomitant with decreased in vitro antiviral activity. Compared with other PEG-IFNa conjugates, the conjugate of this invention has a much greater antiproliferative activity, disproportionate to the enhancement or reduction that occurs in its other characteristics, and virtually no immunogenicity.

The physiologically active PEG-IFNa conjugate species of this invention has the formula:
O

ROCH2CH2(OCH2CH2)n-O-C -NH

( H2)4 JH
R'OCH2CH2(OCH2CH2)n'-O-C-NH \Nc-X- IFNa I I I I

The conjugate of this invention has the same uses as IFNa, for example, antiproliferative uses. In particular, the PEG interferon-a conjugates of this invention are useful to treat immunomodulatory disorders such as neoplastic diseases, for example, hairy cell leukemia, CML, and Kaposi's sarcoma, and infectious diseases, in the same way IFNas (especially IFN(x2a) are used to treat these diseases. However, the conjugate of this invention has improved properties including superior stability, greater solubility, enhanced circulating half-life and plasma residence times. In addition, these conjugates have anti-proliferative activity which is superior to IFNa. Also as noted the conjugate shows a surprising dissociation of antiviral and anti-proliferative effects. This property is additionally useful to enhance a desired activity of a conjugate, while decreasing or eliminating an undesired activity. For example, if an undesired side effect is associated with the antiviral activity, eliminating this activity would eliminate the side effect, while retaining the antiproliferative activity.
Therefore, the present invention also comprises the pharmaceutical compositions on the basis of the compounds of formula I or their salts and to methods for producing them.

The pharmaceutical compositions of the present invention used in the control or prevention of illnesses comprises an interferon conjugate of the general formula I and a therapeutically inert, non toxic and therapeutically acceptable carrier material. The pharma-ceutical compositions to be used can be formulated and dosed in a fashion consistent with good medical practice taking into consideration the disorder to be treated, the condition of the individual patient, the site of delivery of the protein conjugate, the method of administration and other factors known to practitioners.
The claimed conjugate is a physiologically active PEG-IFNa conjugate having the formula ROCH2CH2(OCH2CH2)n-O-C -NH I

( H2)4 L
R'OCH2CH2(OCH2CH2)n'-O-C-NH ~-X- IFNa where R and R' are independently lower alkyl; X is NH or O(X is at least one of the functional groups in the IFNa molecule selected from N H 2 or OH); n and n' are integers having a sum of from 600 to 1500;
and the average molecular weight of the polyethylene glycol units in said conjugate is from about 26,000 daltons to about 66,000 daltons.
The conjugate of formula I has a branched structure, in that two PEG
moieties are attached to the protein via a single linkage.

The numbers n and n' are selected such that the resulting conjugate of Formula I has a physiological activity of IFNa, which activity may represent the same as, more than, or a fraction of the corresponding activity of unmodified IFNa. n and n' (n and n' may be the same or different) represent the number of ethylene glycol units in the PEG. A single PEG unit of OCH2CH2 has a molecular weight of about 44 daltons. The molecular weight of the conjugate (excluding the molecular weight of the IFNa) depends on the numbers n and n'.
The sum of n and n' for the conjugate of Formula I is from 600 to 1500, producing a conjugate having a total average molecular weight of PEG units of from about 26,000 to 66,000 and preferably from about 35,000 to 45,000 daltons, and especially about 39,000 to 45,000 daltons, with 40,000 daltons especially preferred. A preferred sum of n and n' is from about 800 to 1200, with the average sum being from about 850 to 1000, and a preferred sum being about 910. Either of n or n' may individually be 420 or 520, or both may be 420 or 520, or both may be 455. The preferred ratio of n to n' is from about 0.5 to 1.5, with an especially preferred ratio of from about 0.8 to about 1.2.
A molecular weight of "about" a certain number means that it is within a reasonable range of that number as determined by conventional analytical techniques.

Also preferred is a conjugate of Formula I where IFNa is IFNa2a, a conjugate where R and R' are methyl, a conjugate where X is NH, and a conjugate where n and n' are individually or both either 420 or 520. Such a conjugate having all the above characteristics is especially preferred.

R and R' may be any lower alkyl, by which is meant an alkyl group having from one to six carbon atoms such as methyl, ethyl, isopropyl, etc. Branched alkyls are included. A preferred alkyl is methyl. With regard to the two PEG groups of Formula I, R and R' may be the same or different.
By IFNa (interferon a) and its species IFNa2a is meant the natural or recombinant protein, preferably human, as obtained from any conventional source such as tissues, protein synthesis, cell culture with natural or recombinant cells. Any protein having the activity of IFNa , such as muteins or otherwise modified proteins, is encompassed. Obtaining and isolating IFNa from natural or recombinant sources is well known (Pestka, Arch. Biochem. Biophys.
221, 1 (1983)). A preferred IFNa is IFNa2a, which as stated above, is obtained by known methods (Pestka, Sci. Am. 249, 36 (1983);
European Patent No. 43 980)).
The physiologically active conjugate of Formula I has IFNa activity, by which is meant any fraction or multiple of any known IFNa activity, as determined by various assays known in the art. In particular, the conjugates of this invention have IFNa activity as shown by antiproliferative activity against tumor cells and antiviral activity against cells infected with a virus. These are known activities of IFNa. Such activity in a conjugate can be determined by assays well known in the art, for example the assays described below (see also Rubinstein et al., J. Virol. 37, 755 (1981); Borden et al., Canc. Res.
42, 4948 (1982)). Part of this invention is a conjugate of Formula I
which has greater antiproliferative activity and less antiviral activity than unmodified IFNa.

The conjugate of Formula I is produced by covalent linkage of IFNa to PEG which has been activated by replacement of the PEG
hydroxyl with a linking group, forming a reagent which is an N-hydroxy succinimide ester derivative of PEG (in particular monomethoxy PEG) of Formula II. The reagent may be obtained by conventional methods (Monfardini et al., supra). Linkage is via an amide or ester bond. In a preferred conjugate, linkage is via an amide bond (X is NH). Part of this invention is a method for increasing the antiproliferative activity of IFNa while reducing the antiviral activity of the IFNa, by linking the IFNa as described above to a reagent of Formula II to produce a PEG-IFN conjugate.

X represents the attachment site on IFNa by which the PEG
reagent of Formula II is covalently attached to the IFNa. The reagents attach to primary amino groups (XH = NH2) on for example lysine or to the N-terminus of the IFNa. The reagents can also attach to a hydroxyl (XH = OH) on for example serine.
O

ROCH2CH 2(OCH2CH2) n -O-C-NH
I
(CH2)4 II

CH

R'OCH2CH2(OCH2CH2)n'-O-C-NH ~-O-N + XH-IFNa 0 II p 11 0 ROCH2CH2(OCH2CH2)n -O -C -NH

I + HON
(CH2)4 tH O
R'OCH2CH2(OCH2CH2)n -O--C-NH \-X- IFNa II II

The reagent of formula II (PEG2-NHS), in which a total of 2 mono-methoxy PEG (m-PEG) chains are linked to lysine, one each at the a and E amino groups via carbamate (urethane) bonds and having the lysine carboxyl group activated to a succinimidyl ester, may be obtained by conventional methods, according to known procedures (Monfardini et al., supra) applicable to a reagent with R as lower alkyl, and a desired n. The reagent may be obtained from Shearwater Polymers, Inc. (Huntsville, Alabama). The preferred average MW of the PEG obtained is about 20,000 daltons, providing a total PEG mass of about 40,000 daltons in PEG2-NHS (other MWs may be obtained by varying n for the PEG-alcohol starting materials for the reagent of Formula II, by conventional methods).

The reagent of formula II may be conjugated to IFNa by conventional methods. Specifically, the reagent of Formula II
primarily reacts with one or more of the primary amino groups (for example N-terminus and lysine side chains) of IFNa (for example IFNa2a) to form an amide linkage between the IFNa and the polymer backbone of PEG. The PEGylation reaction can also take place between PEG2-NHS and the free (if any) hydroxyl groups (for example serine) of IFNa to form an ester linkage. The reaction mechanism is shown above. The reaction conditions are conventional to a skilled person, and are provided in detail below. The PEG reagent is combined with IFNa under mildly basic conditions at low temperature under conditions suitable for a nucleophilic substitution which will produce the conjugate of Formula I. This is also shown in the above reaction mechanism.

Attaching the reagents to IFNa may be accomplished by conventional methods. PEGs of any selected MW of this invention may be used. Reaction conditions may be selected to provide the claimed conjugate with one reagent attached. The conjugate of Formula I, which has a single reagent of Formula II attached, is separated from unmodified IFNa and conjugates having attached more than one reagent molecule by conventional methods.
Purification methods such as cation exchange chromatography may be used to separate conjugates by charge difference, which effectively separates conjugates into their various molecular weights. The content of the fractions obtained by cation exchange chromatography may be identified by molecular weight using conventional methods, for example, mass spectroscopy, SDS-PAGE, or other known methods for separating molecular entities by molecular weight. A fraction then is accordingly identified which contains the conjugate of Formula I
purified free from unmodified IFNa and from conjugates having more than one reagent attached. In addition, the reagents of Formula II
release one lysine per reagent upon acid hydrolysis, so that the number of lysines in the hydrolysis indicates the number of PEGs attached to the protein, thus the number of reagent molecules attached to a conjugate may be verified.
The following Examples are provided to illustrate the invention and do not limit it in any way. IFNa2a is used in these examples.
Other species of IFNa may also be conjugated to PEG by the methods exemplified.
DESCRIPTION OF THE DRAWINGS

Figure 1: Antitumor activity of the PEG2-IFNalpha2a in nude mice implanted subcutaneously with human renal A498 cells. All animals received a subcutaneous implant of 2 x 106 human renal A498 cells on Study Day -33. On Study Day 0 PEG-IFNalpha2a treatment was initiated. The indicated amount (30, 60, 120 or 300 gg) of PEG2-IFN
alpha2a was administered subcutaneously under the opposite flank of the tumor, 1 time per week for a four week period.
Figure 2: Antitumor activity of IFNalpha2a in nude mice implanted subcutaneously with human renal A498 cells. All animals received a subcutaneous implant of 2 x 106 human renal A498 cells on Study Day -33. On Study Day 0 IFNalpha2a treatment was initiated. The indicated amount (10, 20, 40 or 100 g) of IFNalpha2a was administered subcutaneously under the opposite flank of the tumor, 3 times per week for a four week period.

Figure 3: Antitumor activity of PEG2-IFNalpha2a in nude mice implanted subcutaneously with human renal ACHN cells. All animals received a subcutaneous implant of 2 x 106 human renal ACHN cells on Study Day -25. On Study Day 0 PEG2-IFNalpha2a treatment was initiated. The indicated amount (30, 60, 120 or 300 g) of PEG2-IFNalpha2a was administered subcutaneously under the opposite flank of the tumor, 1 time per week for a five week period.

Figure 4: Antitumor activity of IFNalpha2a in nude mice implanted subcutaneously with human renal ACHN cells. All animals received a subcutaneous implant of 2 x 106 human renal ACHN cells on Study Day -25. On Study Day 0 IFNalpha2a treatment was initiated. The indicated amount (10, 20, 40 or 100 g) of IFNalpha2a was administered subcutaneously under the opposite flank of the tumor, 3 times per week for a five week perid.

Figure 5: Antitumor activity of PEG2-IFNalpha2a in nude mice implanted subcutaneously with human renal G402 cells. All animals received a subcutaneous implant of 2 x 106 human renal G402 cells on Study Day -45. On Study Day 0 PEG2-IFNalpha2a treatment was initiated. The indicated amount (30, 60, 120 or 300 g) of PEG2-IFNalpha2a was administered subcutaneously under the opposite flank of the tumor, 1 time per week for a five week period.

Figure 6: Antitumor activity of IFNalpha2a in nude mice implanted subcutaneously with human renal G402 cells. All animals received a subcutaneous implant of 2 x 106 human renal G402 cells on Study Day -45. On Study Day 0 IFNalpha2a treatment was initiated. The indicated amount (10, 20, 40 or 100 g) of IFNalpha2a was administered subcutaneously under the opposite flank of the tumor, 3 times per week for a five week period.
Example 1 Preparation of conjugate of Formula I
Materials Interferona2a was prepared by known methods (Pestka, supra).
Polyethylene glycol (PEG) reagent of formula II was purchased from Shearwater Polymers, Inc. (Huntsville, Ala). Fractogel EMD CM
650(S) resin, with particle sizes 25-40 m, were supplied by EM
Separations (Gibbstown, MA). Concentrated (lOX) phosphate buffered saline (PBS), pH 7.3, was purchased from BioWhittaker (Walkersville, MD). Sodium dodecyl (laurel) sulfate/polyacrylamide gel electrophoresis (SDS-PAGE) pre-cast gels and electrophoresis units were obtained from NOVEX (San Diego, CA). Concentrated Fast Stain for protein staining of PEG conjugates on SDS-PAGE was purchased from Zoion Research, Inc. (Newton, MA). The LAL endotoxin assay kit was purchased from Associates of Cape Cod, Inc. (Woods Hole, MA).
All other reagents used were of the highest quality available. The jugular cannulated rats and BDF-1 mice were supplied by Charles River Laboratories (Wilmington, MA).
Experimental Procedures A. Small scale preparation of conjugate of Formula I
Two hundred-eight milligrams (5.2 mol) of the. reagent of Formula II (average MW of 40,000 daltons) were added to 50 mg (2.6gmol) of IFNa in lOml of 100mM borate, pH 8Ø Final protein reagent molar ratio was 1:2. The reaction mixture was stirred at 4 C
for 2 hours. The reacrion was stopped by adjusting the pH to 4.5 with glacial acetic acid.

The reaction mixture was diluted 50-fold with water, filtered through a 0.2g filter and applied onto an Amicon column packed with 100m1 (3.2xl3cm) Fractogel EMD CM 650(S), at a flow rate of 20ml/min. The column was previously equilibrated with 10mM
ammonium acetate, pH 4.5. The column effluent was monitored by UV absorbance at 280nm. The column was then washed with the equilibration buffer until UV absorbance returned to baseline. PEG-IFN conjugates having more than one reagent of Formula II attached (PEG-IFN oligomers) were eluted with 40 mM ammonium acetate, pH
4.5 and the conjugate of Formula I was eluted with 0.12M NaCI in the 40 mM ammonium acetate buffer. The unmodified IFN remaining in the column was eluted with 0.5M NaCl in the same buffer. The column was regenerated by a l.OM NaCl wash followed by the equilibration buffer wash. The pooled fractions of the conjugate of Formula I were concentrated in an Amicon stirred cell concentrator fitted with a YM10 membrane to approximately lmg/ml concentration.
The Fractogel CM 650(S) cation exchange resin used for purification, adsorbed the PEG and unmodified IFN effectively. The strength of adsorption was dependent upon the degree of PEGylation.
The conjugates bound less tightly than the unmodified IFN. The PEG-IFN oligomers were eluted with 40mM ammonium acetate, while the conjugate of Formula I eluted with 0.12M NaCl. The unmodified IFN
eluted with 0.5M NaC1. All preparations contained <5EU/mg endotoxins. The resulting preparation contained >99% of conjugate of Formula I and was free of unmodified IFN.
B. Large-Scale Preparation of conjugate of Formula I

Six thousand two hundred and forty milligrams (156 gmol) of the reagent of Formula II (average molecular weight of 40,000 daltons) was dissolved in 63 ml of 1mM HC1 at 4 C and quickly added to 125 ml of a solution containing 1000 mg (52 mol) of interferon in 50 mM borate buffer, pH 9Ø The final protein/reagent ratio was 1:3 and the final reaction mixture protein concentration was 5.3 mg/ml.
The reaction mixture was stirred for 2 hours at 4 C. The reaction was stopped by adjusting the pH to 4.5 with glacial acetic acid.

The reaction mixture was diluted 10-fold with water and applied onto a column packed with 600 ml Fractogel EMD CM 650(M) previously equilibrated with 20mM sodium acetate, pH, 4.5 at a linear velocity of 1.3cm/min. The column was washed with the equilibration buffer followed by 10 mM NaCl to remove excess reagent, reaction byproducts and PEG-IFN oligomers. The conjugate of Formula I was eluted with the equilibration buffer containing 200mM
NaCl. The unmodified interferon still adsorbed to the column was removed by washing with 0.75 M NaCl in the equilibration buffer. The conjugate of Formula I, which was eluted at 0.3-0.5mg/ml was further concentrated and diafiltered into the final formulation buffer, 20 mM
sodium acetate, pH, 5.0, containing 150mM NaCl. The overall yield of the conjugate of Formula I was 40-45%.
The purified PEG-IFN from the large-scale preparation consists of >99% conjugate of Formula I. The average molecular weight of the conjugate of Formula I of this example is 62,000 daltons, including the molecular weight of IFNa2a which is 19,241 daltons, and the average molecular weight of the reagent which is between 40,000 and 45,000 daltons, about 43,000 daltons.

Example 2 Characterization of conjugate of Formula I
Protein Determination Protein concentrations were determined using an A280 value of 1.0 for a lmg/ml solution of IFNa a2a.

SDS-PAGE Analysis The conjugate was analyzed by sodium dodecyl (lauryl) sulfate/polyacrylamide (8-16%) gel electrophoresis, under reducing conditions, according to the methods of Laemmli (Nature 227, 680 (1970)). SDS-PAGE containing PEG-conjugates were stained for protein using Fast Stain (Zoion Research, Inc.) according to the manufacturer's instructions.
Determination of Endotoxin Levels Endotoxin levels were determined using the LAL method, according to the manufacturer's instructions. All preparations contained <5 EU/mg endotoxins.
Example 3 In Vitro Bioactivities of conjugate of Formula I
Antiviral Activity in Bovine Kidney Cells The in vitro antiviral activity of IFNa2a and the conjugate of Formula I as prepared in Example I.A. were determined in a cell culture bioassay employing Madin-Darby bovine kidney (MDBK) cells challenged with vesicular stomatitis virus (Rubinstein et al., supra).
The antiviral activities are listed in Table 1, along with their corresponding residual activities as a percentage of the starting IFN.

Table 1 Anti-Viral Activities Samples PEG Total PEG # Lys Specific Residual Type Mass Modified Activity Activity kDa (U/mg) %
IFNa2a - - - 2.00 x 100 10g Conjugate of Branched 40 1 1.40 x 7 Formula I 10 7 In Vitro Antiproliferative Activity in Human Tumor Cells The in vitro antiproliferative activities were assayed in human Daudi (Burkitt's Lymphoma) cells, as described by Borden et al.
Human Daudi cells were maintained as stationary suspension cultures in RPMI 1540 supplemented with 10% fetal bovine serum and 2 mM
glutamine (Grand Island Biologicals, Grand Island, NY). The cells were screened and found to be free of mycoplasma. Cells (2 x 104) were added to wells of microtiter plates (Costar, MA) in 100 l of medium.
Various concentrations of IFN and the conjugate of Formula I as prepared in Example l.A. were added to the wells in a volume of 100 l. The plates were incubated at 37 C in 5% CO2 for 72 hours.
Cells were pulsed with 0.25 Ci/well of3H-thymidine (New England Nuclear, Boston, MA),. sixteen hours before cell harvesting. The cells were harvested onto glass filters and counted in a liquid scintillation counter. The results were expressed as % inhibition calculated using the formula:

% Inhibition =[(A - B / A] x 100, where;

A = cpm in control culture (cells incubated in medium alone) B = cpm in experimental culture Samples were run in quadruplicate and standard deviation was less than 20% of the mean of all cases. Experiments were run at least twice with comparable results.
The antiproliferative activities (IC50) of IFN and the conjugate are listed in Table 2. The data indicate that there is a 28-fold increase in antiproliferative activity for the conjugate of Formula I, as compared to that of IFN.
Table 2 In Vitro antiproliferative activities in human Daudi (Burkitt's lymphoma) cell lines.
Antiproliferative Activity Sample IC50 (ng/ml) Increase IFNa2a 0.56 lx Conjugate of Formula 1 0.02 28x Example 4 Pharmacokinetics Female Sprague Dawley rats, surgically implanted with jugular cannulas, with an average body weight of 240 - 260g were housed individually, allowed free access to food and water and maintained in a 12 hour light -dark cycle. Within 4 - 6 hours after arrival, jugular cannulas were flushed with PBS. The following day, after flushing with 0.15 - 0.2ml PBS, 2x106 units of IFNa in 0.2 - 0.4m1 PBS were injected, followed by injection of 0.15 - 0.2ml PBS to assure that all drug was washed into the animal. Thus each animal received a dosage of 8x106 IFNa units/kg body weight.

Blood samples were drawn at 5, 15 and 30 minutes, as well as, 1, 3, 5, 12 and 24 hours after injection of IFN and, the conjugate of Formula I. At all time points, after discarding the first 0.15 - 0.2ml of blood, an aliquot of 0.5m1 blood was withdrawn using a fresh syringe via the jugular cannula. The samples were discharged into serum separating tubes at room temperature. Once all the samples were collected for the time points, the tubes were centrifuged at 14,000 x g in a refrigerated Eppendorf centrifuge for 10 minutes. The separated serum was transferred into 1.5m1 microfuge tubes and frozen at -80 C, until ready for bioassay. Serum samples were diluted appropriately and the antiviral activity at each time-point was determined as described. From the plot of time vs. activity, the terminal half-life of the conjugate of Formula I and IFNa were determined and listed in Table 3, which also include plasma residence times.
Table 3 Terminal Half-Lives (t1/2) and Mean Plasma Residence Time Plasma Residence Sample `1/2 (hours) Time (hours) IFNa2 a 2.1 1.0 Conjugate of Formula I 15.0 20.0 Terminal `1/2 estimated by log linear regression.

Example 5 Immunogenicity Normal BDF-1 mice (ten per group) were injected intraperitonially once per day five times per week with various interferon preparations having 300,000 units of antiviral activity.
Some mice were also injected with aggregated form of IFNa2a which is more immunogenic than the monomer form. Blood samples were taken 19 days following the last injection and the serum was evaluated for neutralizing antibodies.
As seen in Table 4, mice injected with IFNa2a produced neutralizing antibodies and this response was greatly increased in mice injected with interferon aggregates. No antibodies were detectable in the majority of animals injected with the conjugate of this invention.
Table 4 Immuno eg nicity Antibody (INU/ml) *
Treatment Median Range IFNa2a 2,400 217- 8, 5 3 3 lo IFNa2a Aggregates 42,667 8,000-768,000 Conjugate of Formula I 0 0-1,133 * Interferon neutralizing units/ml Example 6 Antitumor activity In Vivo The in vivo antitumor activity of a conjugate of Formula I
(PEG2-IFNalpha2a) and unmodified IFNalpha2a were evaluated by determining their ability to reduce the size of various human tumor cells implanted subcutaneously into mice. Results are shown in Figures 1-6.
Procedure: Athymic nude mice (Harlan) received a subcutaneous implant under the left rear flank of 2 x 106 human renal A498 cells (Figures 1 and 2), human renal ACHN cells (Figures 3 and 4), or human renal G402 cells (Figures 5 and 6). 3 to 6 weeks were allowed for the tumors to become established, as indicated. The size criteria for acceptance into the study was 0.05 to 0.50 cubic centimers. The mice were given total weekly doses of PEG2-IFNalpha2a or unmodified IFNalpha2a of 30, 60, 120 or 300 g. In the case of PEG2-IFNalpha2a the mice were treated one time per week (Monday) with 30, 60, 120 or 300 g of PEG2-IFNalpha2a per treatment. In the case of unmodified IFNalpha2a the mice were treated three times per week (Monday, Wednesday, Friday) with 10, 20, 40 or 100 g of IFNalpha2a per treatment. The duration of treatment was 4 to 5 weeks depending on tumor aggressiveness.
Tumor volumes were measured every Monday prior to treatments.
Results: PEG2-IFNalpha2a showed a marked reduction in A498 tumor size as compared to unmodified IFNalpha2a for all weekly dosage levels tested, at 7 days, 14 days, 21 days and 28 days after the beginning of treatment (Figures 1 and 2). Treatment continued for four weeks. Seven days after treatment was discontinued three mice in each group were sacrified. In the three mice treated with PEG2-IFNalpha2a no residual tumor was observed. In mice treated with unmodified IFNalpha2a the A498 tumor weight was 1.28 grams, 0.62 grams, and 1.60 grams respectively in each of three mice. The A498 tumor weight was 2.32 grams, 2.37 grams, and 1.94 grams in each of three control mice. At 80 days after the end of the four week treatment period the existence of tumors was determined by palpation in seven mice. All seven mice were free of tumor tissue by palpation.
PEG2-IFNalpha2a showed a significant reduction in ACHN tumor size as compared to unmodified IFNalpha2a for weekly dosage levels of 60, 120, and 300 g, at 14 days, 21 days, 28 days and 35 days (Figures 3 and 4).
PEG2-IFNalpha2a showed a significant reduction in G402 tumor size as compared to unmodified IFNalpha2a for weekly dosage levels of 60 and 120 g, at 14 days, 21 days, 28 days and 35 days (Figures 5 and 6).

Claims (22)

1. A physiologically active PEG-IFN.alpha. conjugate having the formula wherein R and R' are independently lower alkyl; X is NH or O; n and n' are integers having a sum of from 600 to 1500; and the average molecular weight of the polyethylene glycol units in said conjugate is from about 26,000 daltons to about 66,000 daltons.
2. A conjugate of claim 1 wherein the molecular weight of the polyethylene glycol units is from about 35,000 to about 45,000 daltons.
3. A conjugate of claim 2 wherein the molecular weight of the polyethylene glycol units is about 40,000 daltons.
4. A conjugate of claim 1 wherein R and R' are methyl.
5. A conjugate of claim 1 wherein X is NH.
6. A conjugate of claim 1 wherein the IFN.alpha. is IFN.alpha.2a.
7. A conjugate of claim 1 wherein the average sum of n and n' is 850 to 1000.
8. A conjugate of claim 1 wherein R and R' are methyl; X is NH;
IFN.alpha. is IFN.alpha.2a; and one or both of n and n' is 420.
9. A conjugate of claim 1 wherein R and R' are methyl; X is NH;
IFN.alpha. is IFN.alpha.2a; and one or both of n and n' is 520.
10. A conjugate of claim 1 which has greater antiproliferative activity than IFN.alpha. and less antiviral activity than IFN.alpha..
11. A method for producing a PEG-IFN.alpha. conjugate having an increased antiproliferative activity and decreased antiviral activity as compared to IFN.alpha., which method consists of:

covalently linking a reagent of Formula II

wherein R and R' are independently C1-C6 alkyl;

n and n' are integers having a sum of from 600 to 1500; to XH-IFN.alpha., wherein X is NH or O to produce said PEG-IFN.alpha. conjugate.
12. Pharmaceutical compositions comprising a PEG-IFN.alpha.

conjugate as claimed in any one of claims 1-10 and a therapeutically inert carrier.
13. Pharmaceutical compositions for the treatment or prophylaxis of immunomodulatory disorders comprising a PEG-IFN.alpha.
conjugate as claimed in any one of claims 1-10 and a therapeutically inert carrier.
14. Pharmaceutical compositions according to claim 13 wherein the immunomodulatory disorders are neoplastic diseases.
15. Pharmaceutical compositions according to claim 13 wherein the immunomodulatory disorders are infectious diseases.
16. A use of a PEG-IFN.alpha. conjugate according to any one of claims 1-10 for the manufacture of medicaments for use in the treatment or prophylaxis of immunomodulatory disorders.
17. A use of a PEG-IFN.alpha. conjugate according to any one of claims 1-10 for the manufacture of medicaments for use in the treatment or prophylaxis of infectious diseases.
18. A PEG-IFN.alpha. conjugate as claimed in claims 1-10 prepared according to the method as claimed in claim 11.
19. A use of a PEG-IFN.alpha. conjugate as claimed in claims 1-in the treatment or prophylaxis of immunomodulatory disorders.
20. A use of a PEG-IFN.alpha. conjugate as claimed in claims 1-10 in the treatment or prophylaxis of infectious diseases.
21. A use of a PEG-IFN.alpha. conjugate prepared according to the method as claimed in claim 11 for the manufacture of medicaments for use in the treatment or prophylaxis of immunomodulatory diseases.
22. A use of a PEG-IFN.alpha. conjugate prepared according to the method as claimed in claim 11 in the treatment or prophylaxis of immunomodulatory diseases.
CA002203480A 1996-05-31 1997-04-23 Interferon conjugates Expired - Lifetime CA2203480C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1883496P 1996-05-31 1996-05-31
US60/018,834 1996-05-31

Publications (2)

Publication Number Publication Date
CA2203480A1 CA2203480A1 (en) 1997-11-30
CA2203480C true CA2203480C (en) 2009-06-30

Family

ID=21790006

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002203480A Expired - Lifetime CA2203480C (en) 1996-05-31 1997-04-23 Interferon conjugates

Country Status (47)

Country Link
US (1) US7201897B2 (en)
EP (1) EP0809996B1 (en)
JP (1) JP2980569B2 (en)
KR (1) KR100254097B1 (en)
CN (1) CN1088721C (en)
AR (1) AR008378A1 (en)
AT (1) ATE235920T1 (en)
AU (1) AU725195B2 (en)
BG (1) BG62273B1 (en)
BR (1) BR9703421A (en)
CA (1) CA2203480C (en)
CO (1) CO4950528A1 (en)
CY (2) CY2433B1 (en)
CZ (1) CZ292775B6 (en)
DE (3) DE809996T1 (en)
DK (1) DK0809996T3 (en)
EG (1) EG24292A (en)
ES (1) ES2110386T3 (en)
GR (1) GR970300063T1 (en)
HR (1) HRP970298B1 (en)
HU (1) HU227992B1 (en)
IL (1) IL120902A (en)
IS (1) IS1988B (en)
LU (1) LU91029I2 (en)
MA (1) MA24193A1 (en)
MY (1) MY117909A (en)
NL (1) NL300127I2 (en)
NO (1) NO322964B1 (en)
NZ (1) NZ314903A (en)
OA (1) OA10488A (en)
PA (1) PA8431001A1 (en)
PL (1) PL186949B1 (en)
PT (1) PT809996E (en)
RS (1) RS49533B (en)
RU (1) RU2180595C2 (en)
SA (1) SA97180030B1 (en)
SG (1) SG55314A1 (en)
SI (1) SI0809996T1 (en)
SK (1) SK284458B6 (en)
SV (1) SV1997000049A (en)
TJ (1) TJ328B (en)
TN (1) TNSN97091A1 (en)
TR (1) TR199700358A2 (en)
TW (1) TW517067B (en)
UA (1) UA56989C2 (en)
UY (1) UY24572A1 (en)
ZA (1) ZA974583B (en)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
CA2329474C (en) 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5985263A (en) * 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5981709A (en) * 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
TWI243057B (en) * 1998-03-26 2005-11-11 Schering Corp Formulations for protection of peg-interferon alpha conjugates
KR100622796B1 (en) * 1998-04-28 2006-09-13 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. Polyol-IFN-beta conjugate
SK288038B6 (en) 1998-05-15 2013-01-02 Merck Sharp & Dohme Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
KR20050055053A (en) * 1998-06-08 2005-06-10 에프. 호프만-라 로슈 아게 Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
CN1364089A (en) * 1999-04-08 2002-08-14 先灵公司 Treatment of CML
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
EP1043026B1 (en) 1999-04-08 2005-06-01 Schering Corporation Melanoma therapy
US6923966B2 (en) 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
CZ299516B6 (en) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Erythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
US6313143B1 (en) * 1999-12-16 2001-11-06 Hoffmann-La Roche Inc. Substituted pyrroles
AU782580B2 (en) 2000-01-10 2005-08-11 Maxygen, Inc. G-CSF conjugates
JP2003520247A (en) * 2000-01-24 2003-07-02 シェーリング コーポレイション Combination of temozolomide and pegylated interferon alpha for treating cancer
EP1908477A3 (en) * 2000-01-24 2008-06-11 Schering Corporation Combination of temozolomide and pegylated interferon-alpha for treating cancer
ATE428445T1 (en) 2000-02-11 2009-05-15 Bayer Healthcare Llc CLOTTING FACTOR VII OR VIIA CONJUGATES
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DK1717316T3 (en) 2000-06-30 2008-12-08 Zymogenetics Inc Allelic variant of interferon-like protein Zcyto21
ATE471956T1 (en) * 2001-01-30 2010-07-15 Kyowa Hakko Kirin Co Ltd BRANCHED POLYALKYLENE GLYCOLS
BR0207576A (en) 2001-02-27 2004-04-27 Maxygen Aps Glycosylated variant of an interferon beta precursor (ifnb) polypeptide, processes for increasing the in vivo glycosylation of a precursor ifnb molecule, producing a glycosylated ifnb molecule, preparing a conjugated variant, and treating a mammal with multiple sclerosis pharmaceutical composition , variant ifnb molecule, nucleotide sequence, expression vector, conjugated glycosylation host cell, and use of a conjugate
DE10112825A1 (en) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylation of active ingredients in aqueous solution
ES2291613T3 (en) 2002-01-16 2008-03-01 Biocompatibles Uk Limited CONJUGATES OF POLYMERS.
KR100888371B1 (en) * 2002-01-17 2009-03-13 동아제약주식회사 Antiviral agent including branched polymer derivative and interferon conjugate
DE10209821A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of proteins to a modified polysaccharide
DE10209822A1 (en) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Coupling of low molecular weight substances to a modified polysaccharide
PT1517710E (en) 2002-06-21 2011-07-08 Novo Nordisk Healthcare Ag Pegylated factor vii glycoforms
MXPA05000796A (en) 2002-07-24 2005-04-19 Hoffmann La Roche Polyalkylene glycol acid additives.
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
DE02020425T1 (en) * 2002-09-11 2004-07-15 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
EP1681303B1 (en) * 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
CN100348618C (en) 2002-09-11 2007-11-14 弗雷泽纽斯卡比德国有限公司 Process for producing hydroxyalkyl starch derivatives
TWI318629B (en) * 2002-09-20 2009-12-21 Pharmacia Corp Process for decreasing aggregate levels of pegylated protein
EP1549350B1 (en) 2002-10-08 2008-09-24 Fresenius Kabi Deutschland GmbH Pharmaceutically active oligosaccharide conjugates
US20040219131A1 (en) * 2002-11-18 2004-11-04 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
GB0301014D0 (en) * 2003-01-16 2003-02-19 Biocompatibles Ltd Conjugation reactions
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
CN102516386A (en) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21 derivatives
ES2428358T3 (en) 2003-10-17 2013-11-07 Novo Nordisk A/S Combination therapy
CA2553035A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
CN100355784C (en) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 Method for preparing polyethylene glycol-modified alpha-interferon 1b
EA010501B1 (en) 2004-03-11 2008-10-30 Фрезениус Каби Дойчланд Гмбх Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
CA2566247A1 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
JP2008503217A (en) 2004-06-18 2008-02-07 アンブレツクス・インコーポレイテツド Novel antigen-binding polypeptides and their use
JP2008509889A (en) * 2004-06-30 2008-04-03 イージェン コーポレーション PEGylated interferon alpha-1b
EP1771573A4 (en) 2004-07-21 2009-02-18 Ambrx Inc Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7632491B2 (en) 2004-08-12 2009-12-15 Schering Corporation Stable pegylated interferon formulation
ATE542920T1 (en) 2004-12-22 2012-02-15 Ambrx Inc MODIFIED HUMAN GROWTH HORMONE
EP1861125A2 (en) * 2005-03-23 2007-12-05 Nektar Therapeutics Al, Corporation Conjugates of an hgh moiety and peg derivatives
MX2007014524A (en) 2005-05-18 2008-02-07 Maxygen Inc Evolved interferon-alpha polypeptides.
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
AU2006262151A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
MX2008002149A (en) 2005-08-18 2008-04-22 Ambrx Inc COMPOSITIONS OF tRNA AND USES THEREOF.
JP4261531B2 (en) 2005-09-06 2009-04-30 株式会社Ｎｒｌファーマ Lactoferrin complex and method for producing the same
CN101454461A (en) 2005-11-16 2009-06-10 Ambrx公司 Methods and compositions comprising unnatural amino acids
CN101002944B (en) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 Conjugate of branched chair polymacrogol-interferon, and its preparing method
CN101002945B (en) 2006-01-20 2012-09-05 清华大学 Novel complex used for treating tumor
CN100475270C (en) 2006-01-20 2009-04-08 清华大学 Medicine for treating tumor and application thereof
CN101489580A (en) 2006-05-16 2009-07-22 财团法人东京都医学研究机构 Pharmaceutical composition for treating or preventing hcv infection
EP2213733A3 (en) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
CN1966547B (en) * 2006-11-06 2011-11-09 中国药科大学 Double-chain structured polyethylene glycol derivative preparation and its combination with pharmaceutical molecule
CN101583637B (en) * 2006-11-07 2012-08-08 帝斯曼知识产权资产管理有限公司 Carbamate, thiocarbamate, or urea containing biomolecular fragments
KR101079993B1 (en) 2006-11-17 2011-11-04 동아제약주식회사 Polyethylene glycol-G-CSF conjugate
CN101219219B (en) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 Complex containing vascellum chalone or fragment, preparation method and application thereof
JP5515224B2 (en) 2007-02-28 2014-06-11 日油株式会社 Multi-branched polyoxyalkylene derivatives
CN104163864B (en) 2007-03-30 2017-08-01 Ambrx公司 Through modifying the polypeptides of FGF 21 and its purposes
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
PL2196475T3 (en) 2007-09-04 2012-10-31 Biosteed Gene Expression Tech Co Ltd INTERFERON ALPHA 2a MODIFIED BY POLYETHYLENE GLYCOL, ITS SYNTHESIS PROCESS AND APPLICATION
CN101636414B (en) 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 Interferon alpha 2b modified by polyethylene glycol, its synthesis process and application
US8946148B2 (en) 2007-11-20 2015-02-03 Ambrx, Inc. Modified insulin polypeptides and their uses
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
WO2009090056A2 (en) * 2008-01-18 2009-07-23 F. Hoffmann-La Roche Ag Purification of not-glycosylated polypeptides
ES2733355T3 (en) * 2008-02-01 2019-11-28 Ascendis Pharma As Prodrug comprising a self-cleavable linker
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CN101809038B (en) 2008-04-03 2013-10-30 厦门伯赛基因转录技术有限公司 Growth hormone modified by double-chain polyethylene glycol and its preparation method and application
DK2279007T3 (en) * 2008-04-29 2016-08-22 Ascendis Pharma Growth Disorders Div As Pegylated recombinant relations of human growth hormone
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
NZ590372A (en) 2008-07-08 2012-09-28 Univ Texas Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
HUE035168T2 (en) 2008-09-26 2018-05-02 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
EA201170493A1 (en) 2008-09-26 2011-10-31 Амбркс, Инк. MICROORGANISMS AND VACCINES DEPENDING ON REPLICATION OF NON-NATURAL AMINO ACIDS
IT1399351B1 (en) 2009-06-16 2013-04-16 Fidia Farmaceutici PROCEDURE FOR THE SYNTHESIS OF GLYCOSAMINOGLICAN CONJUGATES (GAG) WITH BIOLOGICALLY ACTIVE MOLECULES, POLYMERIC CONJUGATES AND RELATIVE USES
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
US8822496B2 (en) 2009-10-30 2014-09-02 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy
CA2783296C (en) 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
CN102753573A (en) 2009-12-21 2012-10-24 Ambrx公司 Modified bovine somatotropin polypeptides and uses thereof
CA2791841C (en) 2010-03-05 2023-01-03 Rigshospitalet Chimeric inhibitor molecules of complement activation
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
WO2011161644A1 (en) 2010-06-24 2011-12-29 Panmed Ltd. Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
RU2447083C1 (en) * 2010-07-20 2012-04-10 Закрытое Акционерное Общество "Биокад" NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON
BR112013002532A2 (en) 2010-08-05 2016-05-31 Hoffmann La Roche anti-mhc antibody anti-viral cytokine fusion protein
SI3572091T1 (en) 2010-08-17 2024-07-31 Ambrx, Inc., Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (en) 2010-09-23 2015-04-11 Lilly Co Eli Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2012146630A1 (en) 2011-04-29 2012-11-01 F. Hoffmann-La Roche Ag N-terminal acylated polypeptides, methods for their production and uses thereof
CN102229667A (en) * 2011-06-03 2011-11-02 北京伟嘉人生物技术有限公司 Polyethylene glycol modified porcine alpha-interferon, preparation method and application thereof
CN103930440A (en) 2011-07-01 2014-07-16 拜耳知识产权有限责任公司 Relaxin fusion polypeptide and use thereof
PH12014500283A1 (en) 2011-08-03 2014-03-31 Cytheris Hcv immunotherapy
JP2015509980A (en) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy to treat HCV infection in a population of HCV-HIV co-infected patients
JP2015512900A (en) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy to treat HCV infection in a special patient genotype subpopulation
US9738724B2 (en) 2012-06-08 2017-08-22 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2611788T3 (en) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates thereof, methods for their preparation and methods for use
HRP20190878T1 (en) 2012-08-31 2019-07-26 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EA023323B1 (en) * 2013-03-28 2016-05-31 Илья Александрович МАРКОВ Branched acyl azide pegylating agent, method for preparing the same and method for preparing pegylated interferon
EA022617B1 (en) * 2013-03-28 2016-02-29 Илья Александрович МАРКОВ Monopegylated interferon-alpha of branched structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity
EA021610B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Liquid antiviral formulation
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2554761C1 (en) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Anti-enteroviral and immunostimulating agent
SMT202100388T1 (en) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Modified fgf-21 polypeptides and uses thereof
RS65015B1 (en) * 2014-11-06 2024-01-31 Pharmaessentia Corp Dosage regimen for pegylated interferon
LT3653227T (en) 2014-11-18 2021-03-25 Ascendis Pharma Endocrinology Division A/S Novel polymeric hgh prodrugs
EP3220892B1 (en) 2014-11-21 2021-10-13 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
MX377531B (en) 2015-11-03 2025-03-10 Hoffmann La Roche COMBINATION THERAPY OF AN HBV CAPSID ASSEMBLY INHIBITOR AND AN INTERFERON.
CN106749608B (en) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 Interferon alpha conjugates
WO2018087345A1 (en) 2016-11-14 2018-05-17 F. Hoffmann-La Roche Ag COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
BR112019016139A2 (en) 2017-02-08 2020-04-07 Bristol-Myers Squibb Company modified relaxin polypeptide comprising a pharmacokinetic enhancer and uses thereof
RU2678332C1 (en) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
PL3849614T3 (en) 2018-09-11 2024-04-22 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
CN113366015A (en) 2018-10-19 2021-09-07 Ambrx公司 Interleukin-10 polypeptide conjugates, dimers thereof and uses thereof
WO2020168017A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
SG11202108735QA (en) 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
EP4199968A1 (en) 2020-08-20 2023-06-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
TW202241922A (en) * 2020-12-23 2022-11-01 愛爾蘭商爵士製藥愛爾蘭有限公司 Methods of purifying charge-shielded fusion proteins
MX2023011480A (en) 2021-04-03 2023-12-06 Ambrx Inc ANTI-HER2 ANTIBODY-DRUG CONJUGATES AND USES OF THESE.
WO2024164213A1 (en) 2023-02-09 2024-08-15 谢彦晖 Treatment of atopic dermatitis with polyethylene glycol-modified interleukin 2, glucocorticoid and hyaluronic acid

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
WO1984004745A1 (en) 1983-05-31 1984-12-06 Takeda Chemical Industries Ltd Novel polypeptides and their use
US4681848A (en) 1982-09-22 1987-07-21 Takeda Chemical Industries, Ltd. Novel peptide and use thereof
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
DE3676670D1 (en) 1985-06-26 1991-02-07 Cetus Corp SOLUBILIZATION OF PROTEINS FOR PHARMACEUTICAL COMPOSITIONS BY POLYMER CONJUGATION.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (en) 1987-06-06 1988-12-15 Basf Ag USE OF SALTS OF SULFONAMIDE CARBONIC ACIDS AS CORROSION INHIBITORS IN AQUEOUS SYSTEMS
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5145773A (en) * 1989-05-25 1992-09-08 Sloan-Kettering Institute For Cancer Research Method to detect sensitivity to alpha-interferon therapy
ES2085297T3 (en) * 1989-05-27 1996-06-01 Sumitomo Pharma PROCEDURE FOR PREPARING DERIVATIVES OF POLY (ETHYLENE GLYCOL) AND MODIFIED PROTEIN.
US5238915A (en) 1991-02-08 1993-08-24 Wakunaga Seiyaku K.K. Aromatic composition and method for controlling aroma
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9111967D0 (en) 1991-06-04 1991-07-24 Erba Carlo Spa 2,5'-nucleotide analogs as antiviral agents
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
RU2006036C1 (en) * 1991-12-27 1994-01-15 Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН Method of antigens assay
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
KR960705579A (en) * 1993-11-10 1996-11-08 에릭에스. 딕커 Improved interferon polymer conjugates
WO1995021629A1 (en) * 1994-02-08 1995-08-17 Amgen Inc. Oral delivery of chemically modified proteins
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
CA2458085A1 (en) * 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay

Also Published As

Publication number Publication date
PL186949B1 (en) 2004-04-30
DE69720320T2 (en) 2004-06-03
DK0809996T3 (en) 2003-07-21
HRP970298B1 (en) 2003-08-31
UY24572A1 (en) 2000-12-29
AU2372397A (en) 1997-12-04
JPH1067800A (en) 1998-03-10
RS49533B (en) 2006-12-15
KR100254097B1 (en) 2000-05-01
NO972480D0 (en) 1997-05-30
PT809996E (en) 2003-06-30
EP0809996A3 (en) 1999-04-14
YU17597A (en) 1999-07-28
MX9704012A (en) 1997-11-29
EG24292A (en) 2009-01-08
NZ314903A (en) 1998-10-28
RU2180595C2 (en) 2002-03-20
US20040030101A1 (en) 2004-02-12
DE10399018I1 (en) 2003-10-23
OA10488A (en) 2002-04-11
AR008378A1 (en) 2000-01-19
ZA974583B (en) 1998-11-17
HU227992B1 (en) 2012-08-28
IS1988B (en) 2005-02-15
NO322964B1 (en) 2006-12-18
HUP9700959A2 (en) 1998-03-02
BG101540A (en) 1998-02-27
NO972480L (en) 1997-12-01
EP0809996B1 (en) 2003-04-02
KR970074791A (en) 1997-12-10
EP0809996A2 (en) 1997-12-03
CZ167997A3 (en) 1997-12-17
DE809996T1 (en) 1998-04-09
TW517067B (en) 2003-01-11
PA8431001A1 (en) 2000-05-24
IL120902A0 (en) 1997-09-30
TR199700358A3 (en) 1997-12-21
GR970300063T1 (en) 1998-01-30
CY2433B1 (en) 2004-11-12
SA97180030B1 (en) 2005-11-12
CZ292775B6 (en) 2003-12-17
LU91029I2 (en) 2004-01-23
SI0809996T1 (en) 2003-08-31
SG55314A1 (en) 1998-12-21
SK284458B6 (en) 2005-04-01
AU725195B2 (en) 2000-10-05
SV1997000049A (en) 1998-07-09
TNSN97091A1 (en) 2005-03-15
HU9700959D0 (en) 1997-07-28
JP2980569B2 (en) 1999-11-22
NL300127I2 (en) 2003-09-01
ES2110386T1 (en) 1998-02-16
PL320251A1 (en) 1997-12-08
UA56989C2 (en) 2003-06-16
HRP970298A2 (en) 1998-04-30
CO4950528A1 (en) 2000-09-01
IL120902A (en) 2004-06-20
US7201897B2 (en) 2007-04-10
HUP9700959A3 (en) 1998-03-30
ES2110386T3 (en) 2003-10-01
SK67397A3 (en) 1997-12-10
IS4491A (en) 1997-12-01
CN1088721C (en) 2002-08-07
NL300127I1 (en) 2003-07-01
TJ97000465A (en) 1998-12-25
CN1167777A (en) 1997-12-17
CY2005006I2 (en) 2009-11-04
ATE235920T1 (en) 2003-04-15
TJ328B (en) 2001-12-24
HK1005225A1 (en) 1998-12-31
CA2203480A1 (en) 1997-11-30
MY117909A (en) 2004-08-30
BR9703421A (en) 1998-09-15
MA24193A1 (en) 1997-12-31
CY2005006I1 (en) 2009-11-04
TR199700358A2 (en) 1997-12-21
DE69720320D1 (en) 2003-05-08
BG62273B1 (en) 1999-07-30

Similar Documents

Publication Publication Date Title
CA2203480C (en) Interferon conjugates
TWI232882B (en) Poly-IFN-beta conjugates
AU739359B2 (en) Improved interferon polymer conjugates
HUT75533A (en) Improved interferon polymer conjugates
US20060029573A1 (en) Pegylated interferon alpha-1b
JP2003155299A (en) N-terminally chemically modified protein composition and method
KR20020007296A (en) Gcsf conjugates
CN103228792A (en) PEG-interferon lambda 1 conjugates
HK1005225B (en) Interferon conjugates
JP2009536963A (en) Polyethylene glycol-interferon α conjugate
MXPA97004012A (en) Conjugados de interfe
KR100888371B1 (en) Antiviral agent including branched polymer derivative and interferon conjugate
HK1131345A (en) Polyethylene glycol-interferon alpha conjugate
KR20070110162A (en) Polyethylene Glycol-Interferon Alpha Conjugate

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170424